使用复合终点评分系统评估托珠单抗治疗非感染性葡萄膜炎的疗效:STOP-Uveitis研究
STOP-Uveitis研究是一项2期多中心随机干预临床试验,37例非感染性葡萄膜炎患者每月静脉输注托珠单抗4 mg/kg(第1组)或8 mg/kg(第2组)至第6个月。采用复合终点评分系统评估,第6个月时31例(83.8%)达到阳性临床应答,两组差异无统计学意义(p>0.05)。结论认为两种剂量均有效,复合评分系统可能优于单一指标。
要点
- 第6个月时31例(83.8%)达到阳性临床应答,第1组14例(77.8%),第2组17例(89.5%)。
- 3例(8.1%)治疗失败(均在第1组),3例(8.1%)病情稳定(第1组1例,第2组2例)。
- 两组临床应答差异无统计学意义(p>0.05)。
核心结论
- 两种剂量的静脉托珠单抗在复合终点评分系统下均能改善或维持患者病情稳定。
- 本研究所用的复合评分系统可能比仅用玻璃体混浊或其他单一结局指标更好地评估疗效。
研究设计与样本
- STOP-Uveitis研究为2期多中心随机干预临床试验,数据来自该研究。
- 患者每月接受静脉输注托珠单抗4 mg/kg(第1组)或8 mg/kg(第2组),直至第6个月(M6)。
- 共分析37例患者。
主要发现
- 第6个月时,31例(83.8%)受试者达到阳性临床应答(第1组14例(77.8%),第2组17例(89.5%))。
- 3例(8.1%)受试者(均在第1组)符合治疗失败标准。
- 3例(8.1%)受试者病情稳定(第1组1例,第2组2例)。
- 两组临床应答差异无统计学意义(p>0.05)。
关键数值与推荐
- 复合终点评分系统包括:视力、眼内炎症、黄斑中心凹厚度、荧光血管造影的后节炎症和激素减量。
- 每个组分根据特定标准评分为(+1)改善、(-1)恶化或(0)无变化。
- 临床应答分类:阳性(至少一个参数改善且无任何参数恶化)、阴性(任何参数恶化)、稳定(无改善也无恶化)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: To use a composite endpoint scoring system in assessing efficacy of two doses of intravenous tocilizumab (TCZ), in eyes with non-infectious uveitis. METHODS: Data from STOP-Uveitis Study (a phase 2 multicentre, randomised, interventional clinical trial), where monthly intravenous infusions of 4 mg/kg (Group 1) or 8 mg/kg (Group 2) TCZ until month 6 (M6) were administered, were used. Efficacy was ascertained by a composite endpoint scoring system consisting of: (1) visual acuity; (2) intraocular inflammation; (3) central retinal thickness; (4) posterior segment inflammation on fluorescein angiographic and (5) steroid taper. Each component of grading system was graded as ((+1) improvement, (-1) worsening or (0) no change) based on specific criteria. The clinical response was classified as positive (improvement in at least one parameter and worsening in none), negative (worsening of any parameter) or stable (neither improvement nor worsening of any parameter). The percentage achieving various clinical responses was compared between groups. RESULTS: Thirty-seven patients were analysed. At M6, 31 (83.8%) subjects demonstrated a positive clinical response (Group 1=14 (77.8%) and Group 2=17 (89.5%)). Three (8.1%) subjects (all Group 1) met the criteria for treatment failure, whereas three (8.1%) subjects showed a stable clinical response (Group 1=1 and Group 2=2). The difference in clinical responses between study groups was not significant (p>0.05). CONCLUSIONS: Both doses of intravenous TCZ were effective in either improving or maintaining stability in patients using the composite endpoint scoring system. A composite scoring system as used in this study may be a better measure to assess efficacy outcomes as compared with only vitreous haze or other single outcome measures.
引用
- Hassan M, Sadiq MA, Ormaechea MS, et al. Utilisation of composite endpoint outcome to assess efficacy of tocilizumab for non-infectious uveitis in the STOP-Uveitis Study. Br J Ophthalmol. 2022. PMID: 35379598. doi:10.1136/bjophthalmol-2021-320604
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。